Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GlaxoSmithKline (LSE:GSK; GSK) reported second quarter EPS of 23.9p, up 2p (9%) from the same period last year. The
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury